

VectorXcellerator Programme Guidance

February 2026

1. Programme Overview

1.1 VectorXcellerator is a selective OXB initiative designed to support a limited number of early-stage cell and gene therapy programmes through fully funded feasibility studies.

The purpose of VectorXcellerator is to enable participating organisations (“Applicants”) to generate technical insight to support early development decision-making. Participation in VectorXcellerator does not constitute, and should not be interpreted as, a commitment by either party to enter into any future commercial agreement.

2. Eligibility and Application

2.1 VectorXcellerator is open to cell and gene therapy organisations with an early-stage programme(s) seeking feasibility-level technical evaluation related to viral vector development.

2.2 Submission of an application does not guarantee selection. OXB reserves sole discretion in determining eligibility, suitability, and final selection.

2.3 OXB reserves the right not to award all available feasibility packages if, in its judgement, applications do not meet the required criteria.

3. Selection Process

3.1 Applications will be reviewed by a cross-functional OXB panel with expertise in viral vector development, manufacturing, and analytics.

3.2 Selection will be based on the following criteria:

- Scientific and technical readiness
- Alignment with OXB’s platform capabilities

- Team experience
- Robustness of development plan

3.3 OXB's selection decisions are final and not subject to appeal.

3.4 OXB may contact applicants if further details are needed to assess the application.

4. Feasibility Package Scope

4.1 Each successfully selected Applicant will receive one fully funded feasibility study. The precise scope, deliverables, and timelines will be agreed in writing prior to initiation of any work.

4.2 **Lentiviral Vector (LVV) Feasibility Package:** The LVV VectorXcellerator package is intended to evaluate elements of OXB's LentiVector™ platform process and may include:

- Evaluation of OXB suspension-adapted cell systems and scalable bioreactor technology
- Cloning of the Applicant's gene of interest into OXB genome backbones
- Limited upstream and downstream process evaluation
- A defined set of platform analytical assays
- Generation of feasibility-level data and a summary slide deck

4.3 **AAV Feasibility Package:** The AAV VectorXcellerator package is intended to evaluate elements of OXB's inAAVate™ platform process and may include:

- Evaluation of OXB plasmid-based transfection systems
- Limited upstream bioreactor evaluation and pooled downstream processing
- A defined set of platform analytical assays
- Generation of feasibility-level data, a summary slide deck, and a certificate of testing

4.4 All activities are conducted using research-grade materials and processes.

5. Scope Boundaries and Limitations

5.1 The following are excluded unless agreed separately in writing:

- GMP manufacturing
- Process scale-up beyond small-scale systems
- Regulatory submissions or regulatory advice
- Clinical or commercial supply commitments
- Troubleshooting

5.2 OXB may adjust experimental design, methods, or conditions where scientifically appropriate, provided such adjustments remain within the agreed feasibility objectives.

6. Timelines

6.1 Indicative programme timelines are as follows:

- Applications open: 9th February 2026
- Applications close: 10th April 2026 | 25:59 GMT
- Applicant notification: 12th May 2026
- Feasibility study initiation: To be agreed with selected Applicants

6.2 All timelines are indicative and subject to change based on technical, operational, or resource considerations.

7. Applicant Communications

7.1 All Applicants have the option, at the time of application, to complete a mutual confidentiality agreement in order to complete and submit an application for consideration if required.

7.2 OXB may publicly announce the successfully selected VectorXcellerator applicants by name and/or involve them in case studies, unless otherwise agreed.

7.3 Unsuccessful Applicants will be notified following completion of the review process.

7.4 Participation in VectorXcellerator does not obligate either party to enter into any further agreement.

7.5 OXB reserves the right to modify, suspend, or withdraw the VectorXcellerator initiative at any time prior to commencement of a feasibility study

8. Data, Materials, and Outputs

8.1 OXB has the right to use anonymised data generated during the feasibility studies & information gathered as part of the invite for the VectorXcellerator programme for both internal and external uses. All other rights in respect of data will be addressed in comprehensive terms and conditions prepared by OXB.